<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Giannou AD</submitter><funding>European Research Council</funding><funding>Howard Hughes Medical Institute</funding><pagination>125-142.e12</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9839362</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>56(1)</volume><pubmed_abstract>During metastasis, cancer cells invade, intravasate, enter the circulation, extravasate, and colonize target organs. Here, we examined the role of interleukin (IL)-22 in metastasis. Immune cell-derived IL-22 acts on epithelial tissues, promoting regeneration and healing upon tissue damage, but it is also associated with malignancy. Il22-deficient mice and mice treated with an IL-22 antibody were protected from colon-cancer-derived liver and lung metastasis formation, while overexpression of IL-22 promoted metastasis. Mechanistically, IL-22 acted on endothelial cells, promoting endothelial permeability and cancer cell transmigration via induction of endothelial aminopeptidase N. Multi-parameter flow cytometry and single-cell sequencing of immune cells isolated during cancer cell extravasati</pubmed_abstract><journal>Immunity</journal><pubmed_title>Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22.</pubmed_title><pmcid>PMC9839362</pmcid><funding_grant_id>756017</funding_grant_id><funding_grant_id>715271</funding_grant_id><funding_grant_id>865466</funding_grant_id><pubmed_authors>Starzonek S</pubmed_authors><pubmed_authors>Gao B</pubmed_authors><pubmed_authors>Grass JK</pubmed_authors><pubmed_authors>Scognamiglio P</pubmed_authors><pubmed_authors>Schumacher U</pubmed_authors><pubmed_authors>Carambia A</pubmed_authors><pubmed_authors>Bedke T</pubmed_authors><pubmed_authors>Meiners J</pubmed_authors><pubmed_authors>Flavell RA</pubmed_authors><pubmed_authors>Fard-Aghaie M</pubmed_authors><pubmed_authors>Huber S</pubmed_authors><pubmed_authors>Koch C</pubmed_authors><pubmed_authors>Prinz I</pubmed_authors><pubmed_authors>Briukhovetska D</pubmed_authors><pubmed_authors>Melling N</pubmed_authors><pubmed_authors>Shiri AM</pubmed_authors><pubmed_authors>Tachezy M</pubmed_authors><pubmed_authors>Kaffe E</pubmed_authors><pubmed_authors>Lange T</pubmed_authors><pubmed_authors>Lohse AW</pubmed_authors><pubmed_authors>Cortesi F</pubmed_authors><pubmed_authors>Konczalla L</pubmed_authors><pubmed_authors>Zarogiannis SG</pubmed_authors><pubmed_authors>von Felden J</pubmed_authors><pubmed_authors>Jungraithmayr W</pubmed_authors><pubmed_authors>Bottcher M</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Arap W</pubmed_authors><pubmed_authors>Zigmond E</pubmed_authors><pubmed_authors>Dupree A</pubmed_authors><pubmed_authors>Kobold S</pubmed_authors><pubmed_authors>Wagner J</pubmed_authors><pubmed_authors>Xu H</pubmed_authors><pubmed_authors>Izbicki JR</pubmed_authors><pubmed_authors>Gosalvez JS</pubmed_authors><pubmed_authors>Pasqualini R</pubmed_authors><pubmed_authors>Riethdorf S</pubmed_authors><pubmed_authors>Maroulis IC</pubmed_authors><pubmed_authors>Heumann A</pubmed_authors><pubmed_authors>Plitzko G</pubmed_authors><pubmed_authors>Manthey C</pubmed_authors><pubmed_authors>Zazara DE</pubmed_authors><pubmed_authors>Low JS</pubmed_authors><pubmed_authors>Yamada Y</pubmed_authors><pubmed_authors>Schulze K</pubmed_authors><pubmed_authors>Soukou S</pubmed_authors><pubmed_authors>Wittek A</pubmed_authors><pubmed_authors>Amezcua Vesely MC</pubmed_authors><pubmed_authors>Pantel K</pubmed_authors><pubmed_authors>Karstens KF</pubmed_authors><pubmed_authors>Mann O</pubmed_authors><pubmed_authors>Garcia-Perez L</pubmed_authors><pubmed_authors>Reeh M</pubmed_authors><pubmed_authors>Sabihi M</pubmed_authors><pubmed_authors>Zhao L</pubmed_authors><pubmed_authors>Perez D</pubmed_authors><pubmed_authors>Brockmann L</pubmed_authors><pubmed_authors>Arck PC</pubmed_authors><pubmed_authors>Gagliani N</pubmed_authors><pubmed_authors>May P</pubmed_authors><pubmed_authors>Agalioti T</pubmed_authors><pubmed_authors>Pelczar P</pubmed_authors><pubmed_authors>Guse AH</pubmed_authors><pubmed_authors>Wahib R</pubmed_authors><pubmed_authors>Giannou AD</pubmed_authors><pubmed_authors>Steglich B</pubmed_authors><pubmed_authors>Strowig T</pubmed_authors><pubmed_authors>Huber FJ</pubmed_authors><pubmed_authors>Seese H</pubmed_authors><pubmed_authors>Kempski J</pubmed_authors><pubmed_authors>Zhang T</pubmed_authors><pubmed_authors>Riecken K</pubmed_authors><pubmed_authors>Ghadban T</pubmed_authors><pubmed_authors>Stuben BO</pubmed_authors><pubmed_authors>Lucke J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22.</name><description>During metastasis, cancer cells invade, intravasate, enter the circulation, extravasate, and colonize target organs. Here, we examined the role of interleukin (IL)-22 in metastasis. Immune cell-derived IL-22 acts on epithelial tissues, promoting regeneration and healing upon tissue damage, but it is also associated with malignancy. Il22-deficient mice and mice treated with an IL-22 antibody were protected from colon-cancer-derived liver and lung metastasis formation, while overexpression of IL-22 promoted metastasis. Mechanistically, IL-22 acted on endothelial cells, promoting endothelial permeability and cancer cell transmigration via induction of endothelial aminopeptidase N. Multi-parameter flow cytometry and single-cell sequencing of immune cells isolated during cancer cell extravasati</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-05-27T22:34:05.003Z</modification><creation>2025-04-06T11:11:46.632Z</creation></dates><accession>S-EPMC9839362</accession><cross_references><pubmed>36630911</pubmed><doi>10.1016/j.immuni.2022.12.014</doi></cross_references></HashMap>